Stock Groups

Valneva Stock Surges After EU Vaccine Deal  -Breaking

by Mike Robinson

[ad_1]

© Reuters

Sam Boughedda

Investing.com — French company produces vaccines Valneva SE ADR (NASDAQ:) jumped 24% Wednesday after the European Commission approved an agreement which will allow the company to supply 60 million doses over the next two years. 

The agreement includes roughly 27 million doses of the drug in 2022. However, the EC can increase the initial purchase amount to 60 millions doses at the end 2023.

Following the announcement, Valneva’s shares on Nasdaq were traded at $50.33.

A Dr. Amir Khan article at Al Jazeera explains that Valneva’s vaccine differs from the other Covid-19 vaccines because it stimulates an immune reaction to the whole virus rather than the spike protein.

Valneva CEO Thomas Lingelbach said that “we are committed to bringing an alternate vaccine solution to market as soon and as efficiently as possible.”

““Our Phase 3 results have confirmed many of the benefits associated with inactivated vaccinations, and we believe that our vaccine candidate can make a significant contribution to global efforts to fight the COVID-19 pandemic,” said he.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, futures, indexes and Forex. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]